These results are also consistent with a recently published study that showed the effectiveness of RDEA119, a MEK inhibitor, in reducing MUC2 expression and mucinous tumor growth in in a patient-derived xenograft mouse model of pseudomyxoma peritonei, a mucinous malignancy that arises from the appendix [35]. This evidence concerns the gene MUC2 and mucinous neoplasm.